Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRT106 + Chemotherapy in Advanced Pancreatic Cancer
NCT06866977Phase 2Not yet recruiting
- Sponsor
- Xiangya Hospital, Central South University
- Start
- Mar 2025
- Primary completion
- Oct 2025
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of VRT-106 in pancreatic ductal adenocarcinoma (PDAC), sponsored by Xiangya Hospital, Central South University. Primary endpoint: Safety and tolerability at 3 years. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
VRT-106
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06866977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06866977.